董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Robert J. Spiegel | 男 | Director | 67 | 20.56万美元 | 未持股 | 2017-04-03 |
| John H. Johnson | 男 | lead independent director | 59 | 25.77万美元 | 未持股 | 2017-04-03 |
| Timothy P. Walbert | 男 | Director | 50 | 21.78万美元 | 未持股 | 2017-04-03 |
| Paul R. Edick | 男 | Director | 61 | 20.44万美元 | 未持股 | 2017-04-03 |
| Maureen E. O'Connell | 女 | Director | 55 | 23.15万美元 | 未持股 | 2017-04-03 |
| Peter Greenleaf | 男 | Chairman and Chief Executive Officer | 47 | 433.91万美元 | 未持股 | 2017-04-03 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Max Donley | 男 | Executive Vice President, Global Human Resources, Information Technology and Strategy | 48 | 121.53万美元 | 未持股 | 2017-04-03 |
| Peter Pfreundschuh | 男 | Chief Financial Officer | 48 | 未披露 | 未持股 | 2017-04-03 |
| Matthias Alder | 男 | Executive Vice President, General Counsel and Corporate Secretary | 52 | 110.55万美元 | 未持股 | 2017-04-03 |
| Peter Greenleaf | 男 | Chairman and Chief Executive Officer | 47 | 433.91万美元 | 未持股 | 2017-04-03 |
| Peter Kiener | 男 | Chief Science Officer | 64 | 154.72万美元 | 未持股 | 2017-04-03 |
董事简历
中英对照 | 中文 | 英文- Robert J. Spiegel
-
Robert J. Spiegel于2015年1月成为Sucampo的董事。他是Spiegel Consulting，LLC的总裁兼创始人，自2012年以来一直担任威尔康奈尔医学中心的副教授。 Spiegel博士此前曾于2014年1月至2016年4月担任PTC Therapeutics，Inc.的首席医学官，并于1998年至2009年担任先灵-雅研究所的首席医学官，在1983年加入该公司后，他担任越来越重要的职务。目前担任私人生物技术公司NexImmune，Inc.和Vidac Pharma的董事长。他还自2013年8月起担任Edge Therapeutics，Inc.上市公司的董事会成员，自2010年5月起担任Geron Corporation的董事会成员，并担任许多生物技术公司的顾问。他还担任以色列生物技术基金和全球私募股权投资机构Warburg Pincus的顾问。他曾于2010年5月至2012年1月担任公开上市的生物技术公司Capstone Therapeutics Corp.的董事会成员，并于2010年7月担任公开上市的生物制药公司Talon Therapeutics的董事会成员，直到2013年7月被Spectrum Pharmaceuticals收购为止。收到他的学士学位在耶鲁大学获得博士学位，在宾夕法尼亚大学获得博士学位。
Robert J. Spiegel has served as a director of Geron since May 2010. Dr. Spiegel currently serves as an Associate Professor at the Weill Cornell Medical School, a Senior Advisor to Warburg Pincus, a private equity firm, and an Advisor to the Israel Biotech Fund, a venture investment fund. He is also a member of the board of directors of Ayala Pharmaceuticals, a clinical-stage oncology company, since December 2017; Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing targeted medicines for cancer and other proliferative diseases, since September 2018; Athenex, Inc., a global biopharmaceutical oncology company, since August 2020; and several privately-held biotechnology companies. He previously served as a director for Avior Computing Corporation, a privately-held governance risk and compliance process technology company, from October 2011 to November 2017; Talon Therapeutics, Inc., a biopharmaceutical company, from July 2010 to July 2013; Capstone Therapeutics Corp., a biotechnology company, from May 2010 to January 2012; Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, from January 2015 to January 2018; and PDS Biotechnology Corporation formerly Edge Therapeutics, Inc., a biotechnology company, from August 2013 to March 2019; the Cancer Institute of New Jersey from 1999 to 2009; and Cancer Care New Jersey from 1995 to 2011. From March 2011 to April 2016 Dr. Spiegel served as Chief Medical Officer of PTC Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing treatments for rare disorders. In 2009 after 26 years with the Schering-Plough Corporation (now Merck & Co.), a global healthcare company, Dr. Spiegel retired as Chief Medical Officer and Senior Vice President of the Schering-Plough Research Institute, the pharmaceutical research arm of the Schering-Plough Corporation. His career at Schering-Plough involved various positions, including Director of clinical research for oncology, Vice President of clinical research, and Senior Vice President of worldwide clinical research. Following a residency in internal medicine, Dr. Spiegel completed a fellowship in medical oncology at the National Cancer Institute, and from 1981 to 1999 he held academic positions at the National Cancer Institute and New York University Cancer Center. Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania. - Robert J. Spiegel于2015年1月成为Sucampo的董事。他是Spiegel Consulting，LLC的总裁兼创始人，自2012年以来一直担任威尔康奈尔医学中心的副教授。 Spiegel博士此前曾于2014年1月至2016年4月担任PTC Therapeutics，Inc.的首席医学官，并于1998年至2009年担任先灵-雅研究所的首席医学官，在1983年加入该公司后，他担任越来越重要的职务。目前担任私人生物技术公司NexImmune，Inc.和Vidac Pharma的董事长。他还自2013年8月起担任Edge Therapeutics，Inc.上市公司的董事会成员，自2010年5月起担任Geron Corporation的董事会成员，并担任许多生物技术公司的顾问。他还担任以色列生物技术基金和全球私募股权投资机构Warburg Pincus的顾问。他曾于2010年5月至2012年1月担任公开上市的生物技术公司Capstone Therapeutics Corp.的董事会成员，并于2010年7月担任公开上市的生物制药公司Talon Therapeutics的董事会成员，直到2013年7月被Spectrum Pharmaceuticals收购为止。收到他的学士学位在耶鲁大学获得博士学位，在宾夕法尼亚大学获得博士学位。
- Robert J. Spiegel has served as a director of Geron since May 2010. Dr. Spiegel currently serves as an Associate Professor at the Weill Cornell Medical School, a Senior Advisor to Warburg Pincus, a private equity firm, and an Advisor to the Israel Biotech Fund, a venture investment fund. He is also a member of the board of directors of Ayala Pharmaceuticals, a clinical-stage oncology company, since December 2017; Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing targeted medicines for cancer and other proliferative diseases, since September 2018; Athenex, Inc., a global biopharmaceutical oncology company, since August 2020; and several privately-held biotechnology companies. He previously served as a director for Avior Computing Corporation, a privately-held governance risk and compliance process technology company, from October 2011 to November 2017; Talon Therapeutics, Inc., a biopharmaceutical company, from July 2010 to July 2013; Capstone Therapeutics Corp., a biotechnology company, from May 2010 to January 2012; Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, from January 2015 to January 2018; and PDS Biotechnology Corporation formerly Edge Therapeutics, Inc., a biotechnology company, from August 2013 to March 2019; the Cancer Institute of New Jersey from 1999 to 2009; and Cancer Care New Jersey from 1995 to 2011. From March 2011 to April 2016 Dr. Spiegel served as Chief Medical Officer of PTC Therapeutics, Inc., a biopharmaceutical company focused on discovering and developing treatments for rare disorders. In 2009 after 26 years with the Schering-Plough Corporation (now Merck & Co.), a global healthcare company, Dr. Spiegel retired as Chief Medical Officer and Senior Vice President of the Schering-Plough Research Institute, the pharmaceutical research arm of the Schering-Plough Corporation. His career at Schering-Plough involved various positions, including Director of clinical research for oncology, Vice President of clinical research, and Senior Vice President of worldwide clinical research. Following a residency in internal medicine, Dr. Spiegel completed a fellowship in medical oncology at the National Cancer Institute, and from 1981 to 1999 he held academic positions at the National Cancer Institute and New York University Cancer Center. Dr. Spiegel holds a B.A. from Yale University and an M.D. from the University of Pennsylvania.
- John H. Johnson
-
John H. Johnson，他曾一直担任Xeris Pharmaceuticals, Inc.董事（2013年11月以来）。他曾担任Dendreon Corporation的总裁和首席执行官（从2012年1月到2014年8月）。他此前曾担任Savient Pharmaceuticals公司（一家制药公司）的首席执行官兼董事（从2011年1月到2012年1月）。此前，他曾担任Eli Lilly and Company的肿瘤学单位的高级副总裁兼总裁（从2009年11月到2011年1月）。他也曾担任ImClone Systems Incorporated公司的首席执行官（从2007年到2009年11月），也曾任职于ImClone公司的董事会（直到2008年被Eli Lilly公司收购）。加入ImClone公司之前，他曾担任Johnson & Johnson公司的全球生物制药单位的公司集团主席（从2005年到2007年）、Ortho Biotech Products LP 和Ortho Biotech Canada单位的总裁（从2003年到2005年）、 CNS, Pharmaceuticals Group战略单位的全球副总裁（从2001年到2003年）。他目前担任Tranzyme公司和Dendreon Corporation的董事会主席，以及Cempra公司（一个制药公司临床阶段）的董事。他也担任the Pharmaceutical Research and Manufacturers of America的董事会成员，以及the Health Section Governing Board of Biotechnology Industry Organization的成员。他持有the East Stroudsburg University of Pennsylvania的学士学位。
John H. Johnson has served on Xeris Pharmaceuticals, Inc. board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Mr. Johnson served on the board of directors of Strongbridge since March 2015 and as the Chief Executive Officer of Strongbridge from July 2020 to October 2021. Since March 2022 Mr. Johnson has served as Chief Executive Officer and Director of Reaction Biology Corp., a biotechnology company. Mr. Johnson recently served as a board member of Melinta Pharmaceuticals, Inc. through September 2019 having served as Chief Executive Officer from February 2019 through August 2019 and as interim Chief Executive Officer from October 2018 through February 2019. Mr. Johnson is also a member of the board of directors of Verastem, Inc. also known as Verastem Oncology and Autolus Therapeutics. From January 2012 until August 2014 Mr. Johnson served as the President and Chief Executive Officer of Dendreon Corporation and as its Chairman from January 2012 until June 2014. From January 2011 until January 2012 he served as the Chief Executive Officer and a member of the board of Savient Pharmaceuticals, Inc. From November 2008 until January 2011 Mr. Johnson served as Senior Vice President and President of Eli Lilly and Company's Oncology unit. He was also Chief Executive Officer of ImClone Systems Incorporated, which develops targeted biologic cancer treatments, from August 2007 until November 2008 and served on ImClone's board of directors until it was acquired by Eli Lilly in November 2008. From 2005 to 2007 Mr. Johnson served as Company Group Chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit, President of its Ortho Biotech Products LP and Ortho Biotech Canada units from 2003 to 2005 and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 to 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., OrthoMcNeil Pharmaceutical Corporation and Pfizer, Inc. Mr.Johnson is the former Chairman of Tranzyme Pharma, Inc., former lead independent director of Sucampo Pharmaceuticals, Inc. and a former director of Histogenics Corporation, AVEO Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. He previously served as a member of the board of directors for the Pharmaceutical Research and Manufacturers of America and the Health Section Governing Board of Biotechnology Industry Organization. - John H. Johnson，他曾一直担任Xeris Pharmaceuticals, Inc.董事（2013年11月以来）。他曾担任Dendreon Corporation的总裁和首席执行官（从2012年1月到2014年8月）。他此前曾担任Savient Pharmaceuticals公司（一家制药公司）的首席执行官兼董事（从2011年1月到2012年1月）。此前，他曾担任Eli Lilly and Company的肿瘤学单位的高级副总裁兼总裁（从2009年11月到2011年1月）。他也曾担任ImClone Systems Incorporated公司的首席执行官（从2007年到2009年11月），也曾任职于ImClone公司的董事会（直到2008年被Eli Lilly公司收购）。加入ImClone公司之前，他曾担任Johnson & Johnson公司的全球生物制药单位的公司集团主席（从2005年到2007年）、Ortho Biotech Products LP 和Ortho Biotech Canada单位的总裁（从2003年到2005年）、 CNS, Pharmaceuticals Group战略单位的全球副总裁（从2001年到2003年）。他目前担任Tranzyme公司和Dendreon Corporation的董事会主席，以及Cempra公司（一个制药公司临床阶段）的董事。他也担任the Pharmaceutical Research and Manufacturers of America的董事会成员，以及the Health Section Governing Board of Biotechnology Industry Organization的成员。他持有the East Stroudsburg University of Pennsylvania的学士学位。
- John H. Johnson has served on Xeris Pharmaceuticals, Inc. board of directors since October 2021 in connection with the Strongbridge acquisition. Prior to that, Mr. Johnson served on the board of directors of Strongbridge since March 2015 and as the Chief Executive Officer of Strongbridge from July 2020 to October 2021. Since March 2022 Mr. Johnson has served as Chief Executive Officer and Director of Reaction Biology Corp., a biotechnology company. Mr. Johnson recently served as a board member of Melinta Pharmaceuticals, Inc. through September 2019 having served as Chief Executive Officer from February 2019 through August 2019 and as interim Chief Executive Officer from October 2018 through February 2019. Mr. Johnson is also a member of the board of directors of Verastem, Inc. also known as Verastem Oncology and Autolus Therapeutics. From January 2012 until August 2014 Mr. Johnson served as the President and Chief Executive Officer of Dendreon Corporation and as its Chairman from January 2012 until June 2014. From January 2011 until January 2012 he served as the Chief Executive Officer and a member of the board of Savient Pharmaceuticals, Inc. From November 2008 until January 2011 Mr. Johnson served as Senior Vice President and President of Eli Lilly and Company's Oncology unit. He was also Chief Executive Officer of ImClone Systems Incorporated, which develops targeted biologic cancer treatments, from August 2007 until November 2008 and served on ImClone's board of directors until it was acquired by Eli Lilly in November 2008. From 2005 to 2007 Mr. Johnson served as Company Group Chairman of Johnson & Johnson's Worldwide Biopharmaceuticals unit, President of its Ortho Biotech Products LP and Ortho Biotech Canada units from 2003 to 2005 and Worldwide Vice President of its CNS, Pharmaceuticals Group Strategic unit from 2001 to 2003. Prior to joining Johnson & Johnson, he also held several executive positions at Parkstone Medical Information Systems, Inc., OrthoMcNeil Pharmaceutical Corporation and Pfizer, Inc. Mr.Johnson is the former Chairman of Tranzyme Pharma, Inc., former lead independent director of Sucampo Pharmaceuticals, Inc. and a former director of Histogenics Corporation, AVEO Pharmaceuticals, Inc. and Portola Pharmaceuticals, Inc. He previously served as a member of the board of directors for the Pharmaceutical Research and Manufacturers of America and the Health Section Governing Board of Biotechnology Industry Organization.
- Timothy P. Walbert
-
Timothy P. Walbert，自2010年公司成立起任公司的董事会主席，总裁兼首席执行官。他自2008年6月起也是Horizon Pharma USA的总裁兼首席执行官。2007年5月至2009年6月，他是IDM Pharma, Inc.的总裁、董事兼首席执行官；公司是一家生物制药公司，于2009 年6月被Takeda America Holdings, Inc. 收购。2006年1月至2007年5月，他是NeoPharm, Inc.的商业运营执行副总裁。2001年6月至2005年8月，他是Immunology的区域副总裁兼总经理，在此他领导HUMIRA的全球发展——于2013年超过110亿美元；且是Abbott全球心血管战略执行副总裁，该组织是一家医疗保健公司，现为AbbVie。1998年4月至2001年6月，他是Celebrex North America的董事，以及G.D. Searle & Company 亚太区、拉丁美洲及加拿大的关节炎团队负责人。1991年至1998年，他在G.D. Searle, Merck & Co., Inc.和 Wyeth。担任销售和营销职务。 他持有Muhlenberg College理学士学位。他也在 XOMA Corporation （纳斯达克： XOMA） 、Raptor Pharmaceutical Corp. （纳斯达克： RPTP）、Egalet Corporation （纳斯达克： EGLT）、生物技术工业组织 （BIO）、伊利诺斯州生物技术工业组织 （iBIO）、 ChicagoNEXT、 a World Business Chicago （WBC） led council of technology leaders ，以及芝加哥关节炎基金会（the Greater Chicago Arthritis Foundation）的董事会任职。2013年，他被任命为 伊利诺斯州创新委员会（the Illinois Innovation Council）的主管人员。
Timothy P. Walbert,has served as Horizon Therapeutics Public Limited Company president, chief executive officer and director of Horizon since June 2008 and has served as Horizon Therapeutics Public Limited Company chairman since March 2010. From May 2007 to June 2009, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biotechnology company that was acquired by Takeda America Holdings, Inc. in June 2009. Prior to that, he served as executive vice president, commercial operations of NeoPharm, Inc., a public biotechnology company. From June 2001 to August 2005, Mr. Walbert served as divisional vice president and general manager of immunology, where he built and led the global development and launch of the multi-indication biologic HUMIRA, and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, he served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. Mr. Walbert has served on the boards of directors of Century Therapeutics, Inc., a public biotechnology company, since October 2022, Mirum Pharmaceuticals, Inc., a public biotechnology company, since April 2023, and he sits on the board of directors of the Illinois Biotechnology Innovation Organization (iBIO). Mr. Walbert is also a member of the National Organization for Rare Disorders (NORD) Advisory Board and serves on the Board of Trustees of Muhlenberg College. He previously served as chairman of the board of directors of Exicure, Inc., a public clinical-stage biotechnology company, from July 2019 to February 2022, and on the boards of directors of Aurinia Pharmaceuticals, Inc. a public biotechnology company, from April 2020 to September 2022; Assertio Holdings, Inc., a public specialty pharmaceutical company, from May 2020 to December 2020 (and before that at Zyla Life Sciences, a public pharmaceutical company, from April 2014 until May 2020, when it was acquired by Assertio); and Sucampo Pharmaceuticals, Inc., a public biopharma company, from 2016 to 2018, when it was acquired by Mallinckrodt. Mr. Walbert received his bachelor of arts degree in business from Muhlenberg College, in Allentown, Pennsylvania. - Timothy P. Walbert，自2010年公司成立起任公司的董事会主席，总裁兼首席执行官。他自2008年6月起也是Horizon Pharma USA的总裁兼首席执行官。2007年5月至2009年6月，他是IDM Pharma, Inc.的总裁、董事兼首席执行官；公司是一家生物制药公司，于2009 年6月被Takeda America Holdings, Inc. 收购。2006年1月至2007年5月，他是NeoPharm, Inc.的商业运营执行副总裁。2001年6月至2005年8月，他是Immunology的区域副总裁兼总经理，在此他领导HUMIRA的全球发展——于2013年超过110亿美元；且是Abbott全球心血管战略执行副总裁，该组织是一家医疗保健公司，现为AbbVie。1998年4月至2001年6月，他是Celebrex North America的董事，以及G.D. Searle & Company 亚太区、拉丁美洲及加拿大的关节炎团队负责人。1991年至1998年，他在G.D. Searle, Merck & Co., Inc.和 Wyeth。担任销售和营销职务。 他持有Muhlenberg College理学士学位。他也在 XOMA Corporation （纳斯达克： XOMA） 、Raptor Pharmaceutical Corp. （纳斯达克： RPTP）、Egalet Corporation （纳斯达克： EGLT）、生物技术工业组织 （BIO）、伊利诺斯州生物技术工业组织 （iBIO）、 ChicagoNEXT、 a World Business Chicago （WBC） led council of technology leaders ，以及芝加哥关节炎基金会（the Greater Chicago Arthritis Foundation）的董事会任职。2013年，他被任命为 伊利诺斯州创新委员会（the Illinois Innovation Council）的主管人员。
- Timothy P. Walbert,has served as Horizon Therapeutics Public Limited Company president, chief executive officer and director of Horizon since June 2008 and has served as Horizon Therapeutics Public Limited Company chairman since March 2010. From May 2007 to June 2009, Mr. Walbert served as president, chief executive officer and director of IDM Pharma, Inc., a public biotechnology company that was acquired by Takeda America Holdings, Inc. in June 2009. Prior to that, he served as executive vice president, commercial operations of NeoPharm, Inc., a public biotechnology company. From June 2001 to August 2005, Mr. Walbert served as divisional vice president and general manager of immunology, where he built and led the global development and launch of the multi-indication biologic HUMIRA, and divisional vice president, global cardiovascular strategy at Abbott, now AbbVie. From 1998 to 2001, he served as director, CELEBREX North America and arthritis team leader, Asia Pacific, Latin America and Canada at G.D. Searle & Company. Mr. Walbert has served on the boards of directors of Century Therapeutics, Inc., a public biotechnology company, since October 2022, Mirum Pharmaceuticals, Inc., a public biotechnology company, since April 2023, and he sits on the board of directors of the Illinois Biotechnology Innovation Organization (iBIO). Mr. Walbert is also a member of the National Organization for Rare Disorders (NORD) Advisory Board and serves on the Board of Trustees of Muhlenberg College. He previously served as chairman of the board of directors of Exicure, Inc., a public clinical-stage biotechnology company, from July 2019 to February 2022, and on the boards of directors of Aurinia Pharmaceuticals, Inc. a public biotechnology company, from April 2020 to September 2022; Assertio Holdings, Inc., a public specialty pharmaceutical company, from May 2020 to December 2020 (and before that at Zyla Life Sciences, a public pharmaceutical company, from April 2014 until May 2020, when it was acquired by Assertio); and Sucampo Pharmaceuticals, Inc., a public biopharma company, from 2016 to 2018, when it was acquired by Mallinckrodt. Mr. Walbert received his bachelor of arts degree in business from Muhlenberg College, in Allentown, Pennsylvania.
- Paul R. Edick
-
Paul R. Edick是我们的首席执行官，自2010年7月以来我们的董事会成员。他从2008年到2010年担任GANIC Pharmaceuticals, Inc.的首席执行官。从2006年到2008年他担任MedPointe Inc.的首席执行官（在它被Meda AB收购之前）。他还担任Newlink Genetics Corporation和Circassia Inc.的董事会成员。他从2008年到2011年担任LifeCycle Pharma A/S的董事会主席。他持有纽约克林顿Hamilton College的心理学学士学位。
Paul R. Edick,was first appointed a director of the Company in September 2015. Since January 2017 Mr. Edick has served as President and Chief Executive Officer and a director of Xeris Pharmaceuticals, Inc., a private biotechnology company. Since July 2007 he is also managing partner of 3G Advisors, LLC, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. From July 2010 to November 2014 Mr. Edick served as chief executive officer and a board member of Durata Therapeutics, Inc. Prior to his term at Durata, Mr. Edick was chief executive officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus investment search vehicle, from March 2008 to June 2010 and prior to that was chief executive officer at MedPointe Healthcare, Inc., a position he assumed in 2006 having been their president of pharmaceutical operations since April 2002. He also held a number of senior positions at GD Searle & Company, and at Pharmacia Corporation following its acquisition of the company, culminating in his appointment as Pharmacia’s group vice president and president, Asia Pacific/Latin America. Mr. Edick holds a B.A. in Psychology from Hamilton College. In the past, he served on the Boards of Directors for Amerita, Inc., Veloxis Pharmaceuticals A/S and Informed Medical Communications, Inc. Currently, Mr. Edick serves on the Boards of Directors for Neos Therapeutics, Inc., Sucampo Pharmaceuticals, Inc. and NewLink Genetics Corporation, all of which are public companies. He also serves on the Board of Directors of the private company Iterum Therapeutics Ltd. - Paul R. Edick是我们的首席执行官，自2010年7月以来我们的董事会成员。他从2008年到2010年担任GANIC Pharmaceuticals, Inc.的首席执行官。从2006年到2008年他担任MedPointe Inc.的首席执行官（在它被Meda AB收购之前）。他还担任Newlink Genetics Corporation和Circassia Inc.的董事会成员。他从2008年到2011年担任LifeCycle Pharma A/S的董事会主席。他持有纽约克林顿Hamilton College的心理学学士学位。
- Paul R. Edick,was first appointed a director of the Company in September 2015. Since January 2017 Mr. Edick has served as President and Chief Executive Officer and a director of Xeris Pharmaceuticals, Inc., a private biotechnology company. Since July 2007 he is also managing partner of 3G Advisors, LLC, a consultancy to the pharmaceutical, healthcare and healthcare investor communities. From July 2010 to November 2014 Mr. Edick served as chief executive officer and a board member of Durata Therapeutics, Inc. Prior to his term at Durata, Mr. Edick was chief executive officer of Ganic Pharmaceuticals, Inc., a Warburg Pincus investment search vehicle, from March 2008 to June 2010 and prior to that was chief executive officer at MedPointe Healthcare, Inc., a position he assumed in 2006 having been their president of pharmaceutical operations since April 2002. He also held a number of senior positions at GD Searle & Company, and at Pharmacia Corporation following its acquisition of the company, culminating in his appointment as Pharmacia’s group vice president and president, Asia Pacific/Latin America. Mr. Edick holds a B.A. in Psychology from Hamilton College. In the past, he served on the Boards of Directors for Amerita, Inc., Veloxis Pharmaceuticals A/S and Informed Medical Communications, Inc. Currently, Mr. Edick serves on the Boards of Directors for Neos Therapeutics, Inc., Sucampo Pharmaceuticals, Inc. and NewLink Genetics Corporation, all of which are public companies. He also serves on the Board of Directors of the private company Iterum Therapeutics Ltd.
- Maureen E. O'Connell
-
Maureen E. O'Connell，她于2013年成为董事。2007年以来，她担任Scholastic Inc.的执行副总裁、首席行政官和首席财务官。她全面负责财务、人力资源、信息技术、客户服务、设施、供应链和制造。从2005年到2006年，她担任Affinion Group, Inc.（会员、险和忠诚度项目的领先的亲和力直接营销者）的执行副总裁和首席财务官。从2002年到2004年，她担任一系列职务并不断被提拔，包括Gartner, Inc.（领先的技术研究和咨询公司）的总裁、首席运营官、执行副总裁和首席财务行政官。从2000年到2002年，她在Barnes & Noble担任执行副总裁和首席财务官。从1998年到2000年，她曾在Publishers Clearing House的首席财务官和副总裁。从1997年到1998年，她担任BMG Direct的高级副总裁负责财务和市场分析。从1990年到1997年，她担任Primedia, Inc.的一系列职务，包括最近的高级副总裁和首席财务官。她是Beazer Homes的董事会前成员（2002年到2007年），她在大部分任职期间担任其审计主席。她获得纽约大学（New York University）的斯特恩管理商学院（ Stern School of Business Administration）计和经济学学士学位。她是纽约州的注册会计师。
Maureen E. O'Connell became a Director in February 2013. Since 2007, Ms. O'Connell has been the Executive Vice President, Chief Administrative Officer and Chief Financial Officer at Scholastic Inc. Ms. O'Connell has overall responsibility for finance, human resources, information technology, customer service, facilities, supply chain, and manufacturing. From 2005 to 2006, she served as Executive Vice President and Chief Financial Officer at Affinion Group, Inc., a leading affinity direct marketer of membership, insurance and loyalty programs. From 2002 to 2004, she held a series of progressively more responsible positions, including President and Chief Operating Officer and Executive Vice President, Chief Financial and Administrative Officer at Gartner, Inc., a leading technology research and advisory firm. From 2000 to 2002, she worked at Barnes & Noble, as their Executive Vice President and Chief Financial Officer. From 1998 to 2000, she was the Chief Financial Officer and Vice President at Publishers Clearing House. She worked as the Senior Vice President of Finance and Marketing Analysis at BMG Direct from 1997 to 1998. From 1990 to 1997, she held a series of positions at Primedia, Inc., most recently as Chief Financial Officer and Senior Vice President. Ms. O'Connell is a former member of the board of directors of Beazer Homes from 2002 to 2007, where she served as audit chair for most of her tenure. Ms. O'Connell holds a B.S. in Accounting and Economics from New York University, Stern School of Business Administration and is a Certified Public Accountant in the State of New York. - Maureen E. O'Connell，她于2013年成为董事。2007年以来，她担任Scholastic Inc.的执行副总裁、首席行政官和首席财务官。她全面负责财务、人力资源、信息技术、客户服务、设施、供应链和制造。从2005年到2006年，她担任Affinion Group, Inc.（会员、险和忠诚度项目的领先的亲和力直接营销者）的执行副总裁和首席财务官。从2002年到2004年，她担任一系列职务并不断被提拔，包括Gartner, Inc.（领先的技术研究和咨询公司）的总裁、首席运营官、执行副总裁和首席财务行政官。从2000年到2002年，她在Barnes & Noble担任执行副总裁和首席财务官。从1998年到2000年，她曾在Publishers Clearing House的首席财务官和副总裁。从1997年到1998年，她担任BMG Direct的高级副总裁负责财务和市场分析。从1990年到1997年，她担任Primedia, Inc.的一系列职务，包括最近的高级副总裁和首席财务官。她是Beazer Homes的董事会前成员（2002年到2007年），她在大部分任职期间担任其审计主席。她获得纽约大学（New York University）的斯特恩管理商学院（ Stern School of Business Administration）计和经济学学士学位。她是纽约州的注册会计师。
- Maureen E. O'Connell became a Director in February 2013. Since 2007, Ms. O'Connell has been the Executive Vice President, Chief Administrative Officer and Chief Financial Officer at Scholastic Inc. Ms. O'Connell has overall responsibility for finance, human resources, information technology, customer service, facilities, supply chain, and manufacturing. From 2005 to 2006, she served as Executive Vice President and Chief Financial Officer at Affinion Group, Inc., a leading affinity direct marketer of membership, insurance and loyalty programs. From 2002 to 2004, she held a series of progressively more responsible positions, including President and Chief Operating Officer and Executive Vice President, Chief Financial and Administrative Officer at Gartner, Inc., a leading technology research and advisory firm. From 2000 to 2002, she worked at Barnes & Noble, as their Executive Vice President and Chief Financial Officer. From 1998 to 2000, she was the Chief Financial Officer and Vice President at Publishers Clearing House. She worked as the Senior Vice President of Finance and Marketing Analysis at BMG Direct from 1997 to 1998. From 1990 to 1997, she held a series of positions at Primedia, Inc., most recently as Chief Financial Officer and Senior Vice President. Ms. O'Connell is a former member of the board of directors of Beazer Homes from 2002 to 2007, where she served as audit chair for most of her tenure. Ms. O'Connell holds a B.S. in Accounting and Economics from New York University, Stern School of Business Administration and is a Certified Public Accountant in the State of New York.
- Peter Greenleaf
-
Peter Greenleaf于2016年1月成为Sucampo Pharmaceuticals, Inc.的主席，自2014年3月起担任Sucampo Pharmaceuticals, Inc.的首席执行官和董事会成员。2013年6月至2014年2月，Greenleaf先生担任再生医学公司Historogenics Corporation的首席执行官和董事会成员。2006年至2013年，Greenleaf先生受雇于Medimune LLC，这是阿斯利康的全球生物制剂部门，他最近在阿斯利康担任总裁。2010年1月至2013年6月，Greenleaf先生还担任Medimune Ventures的总裁。Medimune Ventures是阿斯利康集团旗下的一家全资风险投资基金。在担任Medimune总裁之前，Greenleaf先生是Medimune的首席商务官，负责其商业、公司发展和战略职能。Greenleaf先生是Mast Therapeutics，Inc.董事会成员。Mast Therapeutics，Inc.是一家临床阶段的生物制药公司，开发镰状细胞病、心力衰竭和中风的新疗法；Mirna Therapeutics是一家临床阶段的生物制药公司，开发广泛的基于microRNA的肿瘤疗法。Greenleaf先生目前担任Maryland Venture Fund Authority，其愿景是监督InvestMaryland的实施。InvestMaryland是一家公私合作企业，旨在刺激该州的风险资本投资。Greenleaf先生还是美国PhRMA和生物技术产业组织（BIO）药物研究和制造商董事会成员，他在新兴公司部门和健康部门的董事会任职。Greenleaf先生在西康涅狄格州立大学获得学士学位，在圣约瑟夫大学获得工商管理硕士学位。
Peter Greenleaf became our Chairman in January 2016 and has been our Chief Executive Officer and a member of our Board of Directors since March 2014. Prior to his leadership of Sucampo, Mr. Greenleaf served as Chief Executive Officer and member of the Board of Directors of Histogenics Corporation, a regenerative medicine company, from June 2013 to February 2014. From 2006 to 2013 Mr. Greenleaf was employed by MedImmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. Mr. Greenleaf also served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group, from January 2010 to June 2013. Prior to serving as President of MedImmune, Mr. Greenleaf was the Chief Commercial Officer of the company, responsible for its commercial, corporate development and strategy functions. Mr. Greenleaf is a member of the Board of Directors of Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for sickle cell disease, heart failure and stroke, and of Mirna Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics. Mr. Greenleaf currently chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of InvestMaryland, a public-private partnership to spur venture capital investment in the state. Mr. Greenleaf is also a member of the Board of Directors of Pharmaceutical Research and Manufacturers of America PhRMA and Biotechnology Industry Organization (BIO), where he serves on the Governing Boards of the Emerging Companies Section and the Health Section. Mr. Greenleaf earned a bachelor's degree from Western Connecticut State University and a master's degree in business administration from St. Joseph's University. - Peter Greenleaf于2016年1月成为Sucampo Pharmaceuticals, Inc.的主席，自2014年3月起担任Sucampo Pharmaceuticals, Inc.的首席执行官和董事会成员。2013年6月至2014年2月，Greenleaf先生担任再生医学公司Historogenics Corporation的首席执行官和董事会成员。2006年至2013年，Greenleaf先生受雇于Medimune LLC，这是阿斯利康的全球生物制剂部门，他最近在阿斯利康担任总裁。2010年1月至2013年6月，Greenleaf先生还担任Medimune Ventures的总裁。Medimune Ventures是阿斯利康集团旗下的一家全资风险投资基金。在担任Medimune总裁之前，Greenleaf先生是Medimune的首席商务官，负责其商业、公司发展和战略职能。Greenleaf先生是Mast Therapeutics，Inc.董事会成员。Mast Therapeutics，Inc.是一家临床阶段的生物制药公司，开发镰状细胞病、心力衰竭和中风的新疗法；Mirna Therapeutics是一家临床阶段的生物制药公司，开发广泛的基于microRNA的肿瘤疗法。Greenleaf先生目前担任Maryland Venture Fund Authority，其愿景是监督InvestMaryland的实施。InvestMaryland是一家公私合作企业，旨在刺激该州的风险资本投资。Greenleaf先生还是美国PhRMA和生物技术产业组织（BIO）药物研究和制造商董事会成员，他在新兴公司部门和健康部门的董事会任职。Greenleaf先生在西康涅狄格州立大学获得学士学位，在圣约瑟夫大学获得工商管理硕士学位。
- Peter Greenleaf became our Chairman in January 2016 and has been our Chief Executive Officer and a member of our Board of Directors since March 2014. Prior to his leadership of Sucampo, Mr. Greenleaf served as Chief Executive Officer and member of the Board of Directors of Histogenics Corporation, a regenerative medicine company, from June 2013 to February 2014. From 2006 to 2013 Mr. Greenleaf was employed by MedImmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. Mr. Greenleaf also served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group, from January 2010 to June 2013. Prior to serving as President of MedImmune, Mr. Greenleaf was the Chief Commercial Officer of the company, responsible for its commercial, corporate development and strategy functions. Mr. Greenleaf is a member of the Board of Directors of Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for sickle cell disease, heart failure and stroke, and of Mirna Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics. Mr. Greenleaf currently chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of InvestMaryland, a public-private partnership to spur venture capital investment in the state. Mr. Greenleaf is also a member of the Board of Directors of Pharmaceutical Research and Manufacturers of America PhRMA and Biotechnology Industry Organization (BIO), where he serves on the Governing Boards of the Emerging Companies Section and the Health Section. Mr. Greenleaf earned a bachelor's degree from Western Connecticut State University and a master's degree in business administration from St. Joseph's University.
高管简历
中英对照 | 中文 | 英文- Max Donley
Max Donley在2014年6月成为我们人力资源的执行副总裁。加入Sucampo之前，他是MedImmune LLC（AstraZeneca的全球生物制剂分支，他从2000年到2013年在此工作）人力资源和企业事务的执行副总裁。他从1993年到2000年担任Bed, Bath， & Beyond人力资源和发展总监。这项工作有助于建立人力资源基础设施，使公司从12个州的20个地点增长到39个州的254个地点18亿美元的收入。他在Fairfield Resources（他从1992年到1993年在此工作）和R.H. Macy & Co. Inc.（他从1991年到1992年在此工作）开始他的职业生涯。他共同创立Axcelerant Health（医疗技术加速器公司），在那里他仍然是董事会的成员。他获得the University of Michigan的通识学学士学位和George Mason University的工商管理硕士学位。
Max Donley is our Executive Vice President of Global Human Resources, IT and Strategy. Mr. Donley became our Executive Vice President of Human Resources in June 2014. Prior to joining Sucampo, Mr. Donley was the Executive Vice President of Human Resources and Corporate Affairs for MedImmune LLC, the global biologics arm of AstraZeneca, from 2000 to 2013. From 1993 to 2000 Mr. Donley served as the Director of Human Resources and Development at Bed, Bath, & Beyond. Mr. Donley began his career at Fairfield Resources, where he worked from 1992 to 1993 and R.H. Macy & Co. Inc., where he worked from 1991 to 1992. Mr. Donley co-founded Axcelerant Health, a healthcare technology accelerator firm. Mr. Donley earned a bachelor’s degree in general studies from the University of Michigan, and a master’s degree in business administration from George Mason University.- Max Donley在2014年6月成为我们人力资源的执行副总裁。加入Sucampo之前，他是MedImmune LLC（AstraZeneca的全球生物制剂分支，他从2000年到2013年在此工作）人力资源和企业事务的执行副总裁。他从1993年到2000年担任Bed, Bath， & Beyond人力资源和发展总监。这项工作有助于建立人力资源基础设施，使公司从12个州的20个地点增长到39个州的254个地点18亿美元的收入。他在Fairfield Resources（他从1992年到1993年在此工作）和R.H. Macy & Co. Inc.（他从1991年到1992年在此工作）开始他的职业生涯。他共同创立Axcelerant Health（医疗技术加速器公司），在那里他仍然是董事会的成员。他获得the University of Michigan的通识学学士学位和George Mason University的工商管理硕士学位。
- Max Donley is our Executive Vice President of Global Human Resources, IT and Strategy. Mr. Donley became our Executive Vice President of Human Resources in June 2014. Prior to joining Sucampo, Mr. Donley was the Executive Vice President of Human Resources and Corporate Affairs for MedImmune LLC, the global biologics arm of AstraZeneca, from 2000 to 2013. From 1993 to 2000 Mr. Donley served as the Director of Human Resources and Development at Bed, Bath, & Beyond. Mr. Donley began his career at Fairfield Resources, where he worked from 1992 to 1993 and R.H. Macy & Co. Inc., where he worked from 1991 to 1992. Mr. Donley co-founded Axcelerant Health, a healthcare technology accelerator firm. Mr. Donley earned a bachelor’s degree in general studies from the University of Michigan, and a master’s degree in business administration from George Mason University.
- Peter Pfreundschuh
Peter Pfreundschuh自2017年3月起担任我们的首席财务官。他曾于2013年9月至2016年6月担任生物制药公司Immunomedics Inc.的Vice President、财务和首席财务官，并于2016年6月至2016年8月担任该公司的顾问。2008年11月至2013年6月，Pfreundschuh先生是商业医疗设备公司Circulite Inc.的首席财务官。在此之前，Pfreundschuh先生是AstraZeneca Pharmaceuticals L.P.的业务开发和许可执行董事。在AstraZeneca之前，他曾在Johnson and Johnson担任各种职务，包括研发部总监以及营销和全球业务分析总监/总监，以及3D Pharmaceuticals（被Johnson and Johnson收购）的首席财务官/财务主管。Pfreundschuh先生还曾在Alimenterics，Inc.和American Standard Companies，Inc.担任管理职位，并曾是Ernst&Young，LLP的高级审计师。Pfreundschuh先生在莱德大学（Rider University）获得金融学工商管理硕士学位，在罗格斯大学商学院（Rutgers University School of Business）获得会计学工商管理硕士学位，并通过西北大学凯洛格管理学院（Kellogg School of Management）的梦百合执行战略营销课程继续接受教育。他是新泽西州有执照的注册会计师。
Peter Pfreundschuh has served as our Chief Financial Officer since March 2017. He served as Vice President, Finance and Chief Financial Officer of Immunomedics Inc., a biopharmaceutical company, from September 2013 to June 2016 and as a consultant to that company from June 2016 to August 2016. From November 2008 until June 2013 Mr. Pfreundschuh was the Chief Financial Officer of CircuLite Inc., a commercial medical device company. Prior to that, Mr. Pfreundschuh was the Executive Director of Business Development and Licensing for AstraZeneca Pharmaceuticals L.P. Before AstraZeneca, he served at Johnson and Johnson in a variety of capacities, including Controller of the R&D division and Controller/Director of Marketing and Global Business Analytics, as well as Chief Financial Officer/Treasurer for 3 Dimensional Pharmaceuticals, which was acquired by Johnson and Johnson. Mr. Pfreundschuh has also held management positions at Alimenterics, Inc., and American Standard Companies, Inc., and was a Senior Auditor at Ernst & Young, LLP. Mr. Pfreundschuh received an M.B.A. with a concentration in finance from Rider University, a B.S. in accounting from Rutgers University School of Business, and continued his education through the Executive Strategic Marketing Program in Healthcare at the Kellogg School of Management at Northwestern University. He is a licensed Certified Public Accountant in New Jersey.- Peter Pfreundschuh自2017年3月起担任我们的首席财务官。他曾于2013年9月至2016年6月担任生物制药公司Immunomedics Inc.的Vice President、财务和首席财务官，并于2016年6月至2016年8月担任该公司的顾问。2008年11月至2013年6月，Pfreundschuh先生是商业医疗设备公司Circulite Inc.的首席财务官。在此之前，Pfreundschuh先生是AstraZeneca Pharmaceuticals L.P.的业务开发和许可执行董事。在AstraZeneca之前，他曾在Johnson and Johnson担任各种职务，包括研发部总监以及营销和全球业务分析总监/总监，以及3D Pharmaceuticals（被Johnson and Johnson收购）的首席财务官/财务主管。Pfreundschuh先生还曾在Alimenterics，Inc.和American Standard Companies，Inc.担任管理职位，并曾是Ernst&Young，LLP的高级审计师。Pfreundschuh先生在莱德大学（Rider University）获得金融学工商管理硕士学位，在罗格斯大学商学院（Rutgers University School of Business）获得会计学工商管理硕士学位，并通过西北大学凯洛格管理学院（Kellogg School of Management）的梦百合执行战略营销课程继续接受教育。他是新泽西州有执照的注册会计师。
- Peter Pfreundschuh has served as our Chief Financial Officer since March 2017. He served as Vice President, Finance and Chief Financial Officer of Immunomedics Inc., a biopharmaceutical company, from September 2013 to June 2016 and as a consultant to that company from June 2016 to August 2016. From November 2008 until June 2013 Mr. Pfreundschuh was the Chief Financial Officer of CircuLite Inc., a commercial medical device company. Prior to that, Mr. Pfreundschuh was the Executive Director of Business Development and Licensing for AstraZeneca Pharmaceuticals L.P. Before AstraZeneca, he served at Johnson and Johnson in a variety of capacities, including Controller of the R&D division and Controller/Director of Marketing and Global Business Analytics, as well as Chief Financial Officer/Treasurer for 3 Dimensional Pharmaceuticals, which was acquired by Johnson and Johnson. Mr. Pfreundschuh has also held management positions at Alimenterics, Inc., and American Standard Companies, Inc., and was a Senior Auditor at Ernst & Young, LLP. Mr. Pfreundschuh received an M.B.A. with a concentration in finance from Rider University, a B.S. in accounting from Rutgers University School of Business, and continued his education through the Executive Strategic Marketing Program in Healthcare at the Kellogg School of Management at Northwestern University. He is a licensed Certified Public Accountant in New Jersey.
- Matthias Alder
Matthias Alder，他于2014年10月成为我们执行副总裁，负责业务发展和许可。加入Sucampo公司之前，他曾担任Cytos Biotechnology公司（生物制药公司，专注于目标免疫疗法的开发）的负责企业发展和法律事务的执行副总裁，以及公司秘书（从2013年到2014年10月）。从2006年到2012年，他曾担任Micromet公司（被Amgen公司收购）的多种职务，并不断被提拔，包括高级行政副总裁、总法律顾问和秘书、负责法律事务的公司秘书兼合规官、负责人力资源、质量保证、药物安全性和知识产权的经理。他也曾担任Cooley公司的生命科学事务实践合伙人（从1997年到2006年），在那里他代表生物技术公司负责与制药公司的战略事务。职业生涯早期，他曾担任Ciba-Geigy公司、Novartis公司的内部顾问（从1994年到1997年）。他持有the University of Basel、the University of Miami的法律学位，并有资格在瑞士和美国实践法律。
Matthias Alder as served as our Senior Vice President, Chief Business Officer and Company Secretary since July 2017 and as our General Counsel between July 2017 and August 2018. Prior to joining us, he served as executive vice president for business development and licensing from October 2014 to March 2017 and as general counsel and corporate secretary from May 2015 to July 2017 at Sucampo Pharmaceuticals, Inc., a biopharmaceutical company which was subsequently acquired by Mallinckrodt Pharmaceuticals. Prior to this, Mr. Alder served as executive vice president of corporate development and legal affairs and corporate secretary at Cytos Biotechnology AG, a biopharmaceutical company focused on the development of targeted immunotherapies, from 2013 to October 2014. From 2006 to 2012 Mr. Alder held various executive management roles at Micromet, Inc., serving as senior vice president for administration, general counsel and secretary at the time of the acquisition of Micromet by Amgen Inc. in 2012. He was also a partner in the Life Sciences Transactions Practice at Cooley LLP from 1997 to 2006 where he represented biotech companies in strategic transactions with pharmaceutical companies. Earlier in his career, Mr. Alder was in-house counsel at Ciba-Geigy and Novartis. Mr. Alder holds law degrees from the University of Basel and the University of Miami and is qualified to practice law in Switzerland and the United States.- Matthias Alder，他于2014年10月成为我们执行副总裁，负责业务发展和许可。加入Sucampo公司之前，他曾担任Cytos Biotechnology公司（生物制药公司，专注于目标免疫疗法的开发）的负责企业发展和法律事务的执行副总裁，以及公司秘书（从2013年到2014年10月）。从2006年到2012年，他曾担任Micromet公司（被Amgen公司收购）的多种职务，并不断被提拔，包括高级行政副总裁、总法律顾问和秘书、负责法律事务的公司秘书兼合规官、负责人力资源、质量保证、药物安全性和知识产权的经理。他也曾担任Cooley公司的生命科学事务实践合伙人（从1997年到2006年），在那里他代表生物技术公司负责与制药公司的战略事务。职业生涯早期，他曾担任Ciba-Geigy公司、Novartis公司的内部顾问（从1994年到1997年）。他持有the University of Basel、the University of Miami的法律学位，并有资格在瑞士和美国实践法律。
- Matthias Alder as served as our Senior Vice President, Chief Business Officer and Company Secretary since July 2017 and as our General Counsel between July 2017 and August 2018. Prior to joining us, he served as executive vice president for business development and licensing from October 2014 to March 2017 and as general counsel and corporate secretary from May 2015 to July 2017 at Sucampo Pharmaceuticals, Inc., a biopharmaceutical company which was subsequently acquired by Mallinckrodt Pharmaceuticals. Prior to this, Mr. Alder served as executive vice president of corporate development and legal affairs and corporate secretary at Cytos Biotechnology AG, a biopharmaceutical company focused on the development of targeted immunotherapies, from 2013 to October 2014. From 2006 to 2012 Mr. Alder held various executive management roles at Micromet, Inc., serving as senior vice president for administration, general counsel and secretary at the time of the acquisition of Micromet by Amgen Inc. in 2012. He was also a partner in the Life Sciences Transactions Practice at Cooley LLP from 1997 to 2006 where he represented biotech companies in strategic transactions with pharmaceutical companies. Earlier in his career, Mr. Alder was in-house counsel at Ciba-Geigy and Novartis. Mr. Alder holds law degrees from the University of Basel and the University of Miami and is qualified to practice law in Switzerland and the United States.
- Peter Greenleaf
Peter Greenleaf于2016年1月成为Sucampo Pharmaceuticals, Inc.的主席，自2014年3月起担任Sucampo Pharmaceuticals, Inc.的首席执行官和董事会成员。2013年6月至2014年2月，Greenleaf先生担任再生医学公司Historogenics Corporation的首席执行官和董事会成员。2006年至2013年，Greenleaf先生受雇于Medimune LLC，这是阿斯利康的全球生物制剂部门，他最近在阿斯利康担任总裁。2010年1月至2013年6月，Greenleaf先生还担任Medimune Ventures的总裁。Medimune Ventures是阿斯利康集团旗下的一家全资风险投资基金。在担任Medimune总裁之前，Greenleaf先生是Medimune的首席商务官，负责其商业、公司发展和战略职能。Greenleaf先生是Mast Therapeutics，Inc.董事会成员。Mast Therapeutics，Inc.是一家临床阶段的生物制药公司，开发镰状细胞病、心力衰竭和中风的新疗法；Mirna Therapeutics是一家临床阶段的生物制药公司，开发广泛的基于microRNA的肿瘤疗法。Greenleaf先生目前担任Maryland Venture Fund Authority，其愿景是监督InvestMaryland的实施。InvestMaryland是一家公私合作企业，旨在刺激该州的风险资本投资。Greenleaf先生还是美国PhRMA和生物技术产业组织（BIO）药物研究和制造商董事会成员，他在新兴公司部门和健康部门的董事会任职。Greenleaf先生在西康涅狄格州立大学获得学士学位，在圣约瑟夫大学获得工商管理硕士学位。
Peter Greenleaf became our Chairman in January 2016 and has been our Chief Executive Officer and a member of our Board of Directors since March 2014. Prior to his leadership of Sucampo, Mr. Greenleaf served as Chief Executive Officer and member of the Board of Directors of Histogenics Corporation, a regenerative medicine company, from June 2013 to February 2014. From 2006 to 2013 Mr. Greenleaf was employed by MedImmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. Mr. Greenleaf also served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group, from January 2010 to June 2013. Prior to serving as President of MedImmune, Mr. Greenleaf was the Chief Commercial Officer of the company, responsible for its commercial, corporate development and strategy functions. Mr. Greenleaf is a member of the Board of Directors of Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for sickle cell disease, heart failure and stroke, and of Mirna Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics. Mr. Greenleaf currently chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of InvestMaryland, a public-private partnership to spur venture capital investment in the state. Mr. Greenleaf is also a member of the Board of Directors of Pharmaceutical Research and Manufacturers of America PhRMA and Biotechnology Industry Organization (BIO), where he serves on the Governing Boards of the Emerging Companies Section and the Health Section. Mr. Greenleaf earned a bachelor's degree from Western Connecticut State University and a master's degree in business administration from St. Joseph's University.- Peter Greenleaf于2016年1月成为Sucampo Pharmaceuticals, Inc.的主席，自2014年3月起担任Sucampo Pharmaceuticals, Inc.的首席执行官和董事会成员。2013年6月至2014年2月，Greenleaf先生担任再生医学公司Historogenics Corporation的首席执行官和董事会成员。2006年至2013年，Greenleaf先生受雇于Medimune LLC，这是阿斯利康的全球生物制剂部门，他最近在阿斯利康担任总裁。2010年1月至2013年6月，Greenleaf先生还担任Medimune Ventures的总裁。Medimune Ventures是阿斯利康集团旗下的一家全资风险投资基金。在担任Medimune总裁之前，Greenleaf先生是Medimune的首席商务官，负责其商业、公司发展和战略职能。Greenleaf先生是Mast Therapeutics，Inc.董事会成员。Mast Therapeutics，Inc.是一家临床阶段的生物制药公司，开发镰状细胞病、心力衰竭和中风的新疗法；Mirna Therapeutics是一家临床阶段的生物制药公司，开发广泛的基于microRNA的肿瘤疗法。Greenleaf先生目前担任Maryland Venture Fund Authority，其愿景是监督InvestMaryland的实施。InvestMaryland是一家公私合作企业，旨在刺激该州的风险资本投资。Greenleaf先生还是美国PhRMA和生物技术产业组织（BIO）药物研究和制造商董事会成员，他在新兴公司部门和健康部门的董事会任职。Greenleaf先生在西康涅狄格州立大学获得学士学位，在圣约瑟夫大学获得工商管理硕士学位。
- Peter Greenleaf became our Chairman in January 2016 and has been our Chief Executive Officer and a member of our Board of Directors since March 2014. Prior to his leadership of Sucampo, Mr. Greenleaf served as Chief Executive Officer and member of the Board of Directors of Histogenics Corporation, a regenerative medicine company, from June 2013 to February 2014. From 2006 to 2013 Mr. Greenleaf was employed by MedImmune LLC, the global biologics arm of AstraZeneca, where he most recently served as President. Mr. Greenleaf also served as President of MedImmune Ventures, a wholly owned venture capital fund within the AstraZeneca Group, from January 2010 to June 2013. Prior to serving as President of MedImmune, Mr. Greenleaf was the Chief Commercial Officer of the company, responsible for its commercial, corporate development and strategy functions. Mr. Greenleaf is a member of the Board of Directors of Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for sickle cell disease, heart failure and stroke, and of Mirna Therapeutics, a clinical-stage biopharmaceutical company developing a broad pipeline of microRNA-based oncology therapeutics. Mr. Greenleaf currently chairs the Maryland Venture Fund Authority, whose vision is to oversee implementation of InvestMaryland, a public-private partnership to spur venture capital investment in the state. Mr. Greenleaf is also a member of the Board of Directors of Pharmaceutical Research and Manufacturers of America PhRMA and Biotechnology Industry Organization (BIO), where he serves on the Governing Boards of the Emerging Companies Section and the Health Section. Mr. Greenleaf earned a bachelor's degree from Western Connecticut State University and a master's degree in business administration from St. Joseph's University.
- Peter Kiener
Peter Kiener, D.Phil。 ，2013年8月以来，担任我们的首席科学官。从2013年5月到2013年8月，他是New Enterprise Associates的一名企业家。加入New Enterprise Associates之前，从2009年到2013年，他任职于Zyngenia公司。他担任Zyngenia公司的总裁、首席执行官兼联合创始人，该公司专注于开发下一代multi-specific mAb-based生物制剂。加入Zyngenia之前，从2001年到2009年，他担任阿斯利康/ MedImmune生物制剂的研发主管和全球执行副总裁，他帮助建立行业领先的蛋白质和抗体工程，监督多元INDs的提交和新药物的应用。在加入MedImmune之前，从1983年到2001年，他在Bristol-Myers Squibb不同领域担任科学家，然后担任经理，他用了十年时间研究生物疗法。他获得英国兰开斯特大学的化学学士学位，英国牛津大学的生物化学学位。他在同行评议的杂志上发表了120多篇论文，拥有30多项专利和专利申请。
Peter Kiener became our Chief Science Officer in October 2014. Prior to joining Sucampo, he served as Chief Scientific Officer of Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates, from August 2013 to September 2014. From 2009 to August 2013 Dr. Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company. He also held leadership roles of increasing responsibility from 2001 to 2009 at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. Dr. Kiener worked on biologics for Bristol-Myers Squibb from 1983 to 2001. He started his career at the University of North Texas/Texas College of Osteopathic Medicine, where he was an Assistant Professor from 1982 to 1983 and the University of Massachusetts at Amherst, where he was a Research Associate from 1978 to 1982. Dr. Kiener currently serves as a director of the private companies Resolve Therapeutics, LLC, Cue Biopharma, Inc. and Tetragenetics, Inc. He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications. He earned a bachelor’s degree in chemistry from the University of Lancaster and a doctorate of philosophy in biochemistry from the University of Oxford.- Peter Kiener, D.Phil。 ，2013年8月以来，担任我们的首席科学官。从2013年5月到2013年8月，他是New Enterprise Associates的一名企业家。加入New Enterprise Associates之前，从2009年到2013年，他任职于Zyngenia公司。他担任Zyngenia公司的总裁、首席执行官兼联合创始人，该公司专注于开发下一代multi-specific mAb-based生物制剂。加入Zyngenia之前，从2001年到2009年，他担任阿斯利康/ MedImmune生物制剂的研发主管和全球执行副总裁，他帮助建立行业领先的蛋白质和抗体工程，监督多元INDs的提交和新药物的应用。在加入MedImmune之前，从1983年到2001年，他在Bristol-Myers Squibb不同领域担任科学家，然后担任经理，他用了十年时间研究生物疗法。他获得英国兰开斯特大学的化学学士学位，英国牛津大学的生物化学学位。他在同行评议的杂志上发表了120多篇论文，拥有30多项专利和专利申请。
- Peter Kiener became our Chief Science Officer in October 2014. Prior to joining Sucampo, he served as Chief Scientific Officer of Ambrx Inc., a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates, from August 2013 to September 2014. From 2009 to August 2013 Dr. Kiener was President and Co-founder of Zyngenia Inc., an early-stage biopharmaceutical company. He also held leadership roles of increasing responsibility from 2001 to 2009 at MedImmune LLC, the global biologics arm of AstraZeneca, including Executive Vice President and Global Head of Biologics Research and Development, Senior Vice President and Head of Global Research, and Vice President of Research. Dr. Kiener worked on biologics for Bristol-Myers Squibb from 1983 to 2001. He started his career at the University of North Texas/Texas College of Osteopathic Medicine, where he was an Assistant Professor from 1982 to 1983 and the University of Massachusetts at Amherst, where he was a Research Associate from 1978 to 1982. Dr. Kiener currently serves as a director of the private companies Resolve Therapeutics, LLC, Cue Biopharma, Inc. and Tetragenetics, Inc. He has published more than 120 papers in peer-reviewed journals and is an inventor on more than 40 patents and patent applications. He earned a bachelor’s degree in chemistry from the University of Lancaster and a doctorate of philosophy in biochemistry from the University of Oxford.